Tacrolimus: Difference between revisions
(contraindications) |
(serious effects) |
||
| Line 56: | Line 56: | ||
==Adverse Reactions== | ==Adverse Reactions== | ||
===Serious=== | ===Serious=== | ||
*immunosuppression | |||
*malignancy | |||
*lymphoma | |||
*post-transplant lymphoproliferative disorder | |||
*infection, severe | |||
*CMV | |||
*PML | |||
*BK virus-assoc. nephropathy | |||
*Stevens-Johnson syndrome | |||
*toxic epidermal necrolysis | |||
*anaphylaxis | |||
*nephrotoxicity | |||
*neurotoxicity | |||
*posterior reversible encephalopathy syndrome | |||
*seizures | |||
*myocardial hypertrophy | |||
*pericardial effusion | |||
*QT prolongation | |||
*torsades de pointes | |||
*hyperkalemia, severe | |||
*HTN, severe | |||
*diabetes mellitus | |||
*myelosuppression | |||
*DIC | |||
*thrombocytopenic purpura | |||
*hemolytic anemia | |||
*pure red cell aplasia | |||
===Common=== | ===Common=== | ||
Revision as of 03:28, 9 February 2016
Administration
- Type: immunosuppressant
- Dosage Forms: 0.5,1,5
- Routes of Administration: PO, topical, IV
- Common Trade Names:Prograf
Adult Dosing
Heart transplant rejection prophylaxis
- 0.075 mg/kg/day PO divided q12h
- Start: >6h post-transplant; Info: adjust dose based on serum levels
Liver transplant rejection prophylaxis
- 0.1-0.15 mg/kg/day PO divided q12h
- Start: >6h post-transplant; Info: adjust dose based on serum levels
Kidney transplant rejection prophylaxis
- 0.1-0.2 mg/kg/day PO divided q12h
- Start: w/in 24h post-transplant; delay if renal fxn not adequate; Info: adjust dose based on serum levels
Pediatric Dosing
Liver transplant rejection prophylaxis
- 0.15-0.2 mg/kg/day PO divided q12h
- Start: >6h post-transplant; Info: adjust dose based on serum levels
Special Populations
- Pregnancy Rating: Pregnancy Category C
- Lactation risk: possibly unsafe
Renal Dosing
- Adult:
- kidney transplant: give lowest recommended dose, may consider further dose decr.; postop oliguria: start 6-24h post-transplant; may delay until renal fxn adequate; HD: not defined
- all other transplants: give lowest recommended dose, may consider further dose decr.; HD: not defined
- Pediatric: give lowest recommended dose, may consider further dose decr.; HD: not defined
Hepatic Dosing
- Adult: give lowest recommended dose, may consider further dose decr.; Child-Pugh Score >10: decr. dose, amount not defined
- Pediatric: give lowest recommended dose, may consider further dose decr.; Child-Pugh Score >10: decr. dose, amount not defined
Contraindications
- Allergy to class/drug
- hypersensitivity to castor oil derivatives (IV form)
- liver transplant use (ER cap form)
- electrolyte abnormalities, uncorrected
- congenital long QT syndrome
- caution if QT prolongation
- caution if QT prolongation family hx
- caution if torsades de pointes hx
- caution if ventricular arrhythmias
- caution if bradycardia
- caution if recent MI
- caution if CHF
- caution in female pts
- caution in black pts
- caution in Hispanic pts
- caution if renal impairment
- caution if hepatic impairment
Adverse Reactions
Serious
- immunosuppression
- malignancy
- lymphoma
- post-transplant lymphoproliferative disorder
- infection, severe
- CMV
- PML
- BK virus-assoc. nephropathy
- Stevens-Johnson syndrome
- toxic epidermal necrolysis
- anaphylaxis
- nephrotoxicity
- neurotoxicity
- posterior reversible encephalopathy syndrome
- seizures
- myocardial hypertrophy
- pericardial effusion
- QT prolongation
- torsades de pointes
- hyperkalemia, severe
- HTN, severe
- diabetes mellitus
- myelosuppression
- DIC
- thrombocytopenic purpura
- hemolytic anemia
- pure red cell aplasia
Common
Pharmacology
- Half-life:
- Metabolism:
- Excretion:
